APA (7th ed.) Citation

N, L., A, B., H, F., D, E., G, K., BN, B., . . . S, D. (2025). Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma. Blood cancer discovery, 6(3), 182. https://doi.org/10.1158/2643-3230.BCD-24-0178

Chicago Style (17th ed.) Citation

N, Liebers, et al. "Brexucabtagene Autoleucel Versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma." Blood Cancer Discovery 6, no. 3 (2025): 182. https://doi.org/10.1158/2643-3230.BCD-24-0178.

MLA (9th ed.) Citation

N, Liebers, et al. "Brexucabtagene Autoleucel Versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma." Blood Cancer Discovery, vol. 6, no. 3, 2025, p. 182, https://doi.org/10.1158/2643-3230.BCD-24-0178.